Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)
Information source: Asan Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hepatocellular Carcinoma; Metastasis
Intervention: Conventional Transarterial Chemoembolization (TACE) (Procedure); sorafenib (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Asan Medical Center Official(s) and/or principal investigator(s): Kang Mo Kim, MD, PhD, Principal Investigator, Affiliation: Asan Medical Center, University of Ulsan
Overall contact: Kang Mo Kim, MD, PhD, Phone: 82230105812, Email: kimkm70@amc.seoul.kr
Summary
This study is a phase II, prospective, open-label, single arm, single center study of the
efficacy and safety of concurrent conventional transarterial chemoembolization (TACE) and
sorafenib in patients with hepatocellular carcinoma and extrahepatic metastasis. All of the
55 patients with hepatocellular carcinoma and newly diagnosed extrahepatic (lung, bone,
lymph node, adrenal gland) metastasis will be included.
On demand conventional TACE will be performed in all the patients after enrollment and can
be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be
started 3-7 days after the first and each subsequent TACE and stopped one day before next
TACE and will be continued until sorafenib failure, consent withdrawal or condition
worsening by clinical decision. Repeated on-demand TACE and sorafenib should continue until
the criteria for treatment discontinuation are met. After initiation of sorafenib
combination treatment, patients will be seen and will perform routine examination at week 4
and, after then routine examination will be followed every 6 ± 2 weeks.
Clinical Details
Official title: A Phase II, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Concurrent Conventional TACE and Sorafenib in Patients With Hepatocellular Carcinoma and Extrahepatic Metastasis (COTSOM Study)
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Overall survival (OS)
Secondary outcome: Safety (adverse events and laboratory values)Liver dysfunction (laboratory values related to liver) Time to progression (TTP) Time to TACE failure (TTTF) Time to sorafenib failure (TTSF) Tumor response rate (TRR) Disease control rate (DCR)
Detailed description:
This is a single center, single arm, prospective, phase II study in patients with metastatic
HCC. A total of 55 patients with HCC and newly diagnosed extrahepatic (lung, bone, lymph
node, adrenal gland) metastasis will be enrolled.
On demand conventional TACE will be performed in all the patients after enrollment and can
be continued until intrahepatic CR, TACE failure or consent withdrawal. Safety will be
evaluated every 6 ± 2 weeks after initial TACE and closed monitoring at unscheduled visit
will be done as well. The efficacy of TACE will be evaluated every 6 ± 2 weeks after each
session of TACE using dynamic CT or MRI. Performance of repeated TACE will be decided based
on the findings of follow-up CT, patients' liver function and performance status, within 6 ±
2 weeks of the previous TACE. Patients with no residual viable tumors after previous TACE
who are not indicated for further TACE are evaluated with routine examination and imaging
studies every 6 ± 2 weeks. Safety should be evaluated on an ongoing basis and within 3 days
of next TACE. All eligible patients will be given sorafenib (initially 400mg po bid) on day
3-7 after the first or every session of TACE, and sorafenib will be stopped one day before
each TACE. Sorafenib will be continued until sorafenib failure, consent withdrawal or
condition worsening by clinical decision. Treatment failure will be judged by the evaluation
of intra- or extrahepatic lesion separately. TACE failure is defined as when
TACE/transarterial chemo-lipiodolization (TACL) has no more benefit by clinical assessment
which is judged clinically by one investigator and/or the patient is not more eligible
because of worsening of ECOG PS or liver function. Detailed criteria for stopping TACE will
be clarified in below. Sorafenib failure will be evaluated by modified RECIST applied to the
extrahepatic lesion, and sorafenib will be stopped when progressive disease (PD) by mRECIST
for extrahepatic lesion is indicated and clinical benefit of TACE is not expected for
intrahepatic lesion. As long as TACE is evaluated to be beneficial and planned to be
performed by investigator, sorafenib could be continued if side effect is tolerable.
When any of the treatment discontinuation criteria is met, test treatment will be stopped.
Survival and post-treatment information will be collected at 1-3 months intervals after the
last study visit until the endpoint of death, or until the subject has become lost to
follow-up or until study termination by Principal Investigator. Additional palliative
anti-cancer therapies such as cytotoxic chemotherapy and TACL without gelfoam embolization
and palliative radiation therapy will be allowed and recorded.
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with HCC and newly diagnosed extrahepatic metastasis meeting of following
criteria
1. Clinical or histological diagnosis of HCC based on the guidelines: Early
enhancement followed by late wash-out on dynamic liver imaging (CT or MRI) Or
Pathological examination of liver biopsy
2. Evidence of extrahepatic metastasis with any of following methods; CT, MRI, bone
scan, positron emission tomography with FDG-PET, biopsy of metastatic lesion
3. Preserved liver function classified as Child-Pugh A
4. ECOG PS of 0-1
5. Age of at least 20 years
6. Patients is able to comply with scheduled visits, evaluation plan, and other
study procedures
7. Patient is willing to provide written informed consent
8. There is no limitation of prior TACE session number in case that further TACE is
still considered to be beneficial
9. Women of childbearing potential must have a negative pregnancy test performed
within 14 days of the start of treatment. All patients of child-bearing
potential must use adequate birth control measures during the course of the
trial (barrier method of birth control) and up to at least 30 days of last dose.
Exclusion Criteria:
- Presence of any of following criteria
1. Patients who are diagnosed as not eligible for further TACE before screening
2. Patients with advanced liver disease as defined below:
- Child Pugh B and C
- Encephalopathy
- Ascites
3. Complete occlusion of main portal vein (PV) by HCC
4. Patients with brain metastasis
5. Inadequate liver function that could not perform TACE:
- AST > 5 X ULN(upper limit normal) or ALT > 5 X ULN
- Total bilirubin > 2. 0 mg/dL
- Prothrombin time INR > 1. 7
6. Inadequate bone marrow function (absolute neutrophil count < 1,500/μL,
Hemoglobin (Hgb) < 8 g/dL, platelet count < 50,000/μL)
7. Inadequate renal function (creatinine > 1. 5 x ULN)
8. Treatment with previous local therapy such as resection of HCC, radiofrequency
ablation (RFA), percutaneous ethanol injection (PEI) < 4 weeks prior to the
screening
9. Prior sorafenib use
10. Investigational drugs or other molecular target drugs ongoing or completed < 4
weeks prior to the screening
11. Clinically significant gastrointestinal bleeding within 4 weeks prior to start
of study drug
12. Uncontrolled bleeding varices.
13. History of cardiac disease:
- Congestive heart failure >NYHA class 2
- Active coronary artery disease (CAD) (myocardial infarction more than 6
months prior to study entry is allowed)
- Unstable angina (anginal symptoms at rest), new-onset angina within 3
months before screening
- Cardiac arrhythmias which are poorly controlled with anti-arrhythmic
therapy or requiring pace maker
- Uncontrolled hypertension
14. Active clinically serious infections except for HBV and HCV infection
15. Patients with HIV
16. Subjects with thrombotic, embolic, venous, or arterial events, such as
cerebrovascular accident (including transient ischemic attacks) within 6 months
before screening
17. Recently treated or concurrent cancer that has a primary site or histology
distinct from HCC except any cancer curatively treated more than 3 years prior
to screening
18. Pregnant or breast-feeding subjects
19. Major surgery, open biopsy, or significant traumatic injury 4 weeks before
screening
20. Presence of a non-healing wound, non-healing ulcer, or bone fracture
21. Subjects who have used strong CYP3A4 inducers within 4 weeks before screening
22. Known or suspected allergy or hypersensitivity to any of the study drugs, study
drug classes, or excipients of the formulations given during the course of this
trial
23. Any other condition which, in the opinion of the investigator, would make the
patient unsuitable for enrollment or could interfere with the completing the
study
Locations and Contacts
Kang Mo Kim, MD, PhD, Phone: 82230105812, Email: kimkm70@amc.seoul.kr
Asan Medical Center, Seoul, Korea, Republic of; Recruiting Kang Mo Kim, MD, PhD, Phone: 82230105812, Email: kimkm70@amc.seoul.kr
Additional Information
Related publications: Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007;72 Suppl 1:30-44. Epub 2007 Dec 13. Review. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009 May;24(5):806-14. doi: 10.1111/j.1440-1746.2008.05728.x. Epub 2009 Jan 13. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339-64. doi: 10.1159/000327577. Epub 2011 Aug 9. Yoo DJ, Kim KM, Jin YJ, Shim JH, Ko GY, Yoon HK, Sung KB, Lee JL, Kang YK, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol. 2011 Jan;26(1):145-54. doi: 10.1111/j.1440-1746.2010.06341.x. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. Review.
Starting date: December 2014
Last updated: December 8, 2014
|